title: Loracarbef versus cefaclor in the treatment of urinary tract infections in women.
abstract: In a double-blind, prospective, randomized study, 108 college women with acute urinary tract infections were treated for 7 days with either loracarbef (LY163892) at 200 mg once daily (n = 53) or cefaclor at 250 mg three times daily (n = 55). The cure rates at 5 to 9 days after treatment in the loracarbef and cefaclor groups were 96 and 90%, respectively. Both loracarbef and cefaclor are safe, well tolerated, and effective in the treatment of urinary tract infections in women.
authors.affiliation: Department of Pediatrics, College of Medicine, University of Florida, Gainesville 32610-0296.
authors.forename: A
authors.initials: A
authors.lastname: Iravani
mesh_terms: D002433:Cefaclor / Q000009:adverse effects / Q000627:therapeutic use*; D002511:Cephalosporins / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000382:microbiology
chemical_list: D002511:Cephalosporins; C054920:loracarbef; D002433:Cefaclor